Training facilitators in psilocybin, ketamine & psychedelic therapy. Research, integration & harm reduction for a healthier future. #Psychedelics
Vancouver, British Columbia
Joined March 2019
- Tweets1.2K
- Following97
- Followers7.7K
- Likes1.5K
Numinus retweeted
CYB003’s Phase 2 results show not only groundbreaking efficacy but also a strong safety profile, paving the way for a brighter future in Major Depressive Disorder (#MDD care).
Learn more: cybin.com
#MentalHealthInnovation #Neuropsychiatry #BreakthroughTherapy
Numinus retweeted
We know psychedelic therapy can improve mental health for specific conditions, but most research focuses on one-on-one treatment. A new study suggests group therapy may unlock even greater potential. Could this be the key to healing?
doubleblindmag.com/psychedel…
Numinus retweeted
In this episode, Joe interviews @RickDoblin, Ph.D., founder of @MAPS. He discusses the FDA's rejection of MDMA-assisted therapy for PTSD, the FDA's bias towards harshness, the importance of sharing positive psychedelic experiences, and more.🧑🔬
🎧️: psychedelicstoday.com/2024/1…
Numinus retweeted
A connection between the gut microbiome and LSD?
Check out the post to find out more...
Numinus retweeted
FINAL DAYS! Share your perspectives before the EXPAND survey closes Sept 20th! Prescribers What do you appreciate about the SAP process? What could be better? (survey will take 15-20 min, responses are confidential) bit.ly/EXPANDStudy
Numinus retweeted
CPCR Director Dr. Frederick Barrett (@FredBarrettPhD) discusses blinding and study design options for psychedelic clinical trials. Check it out in MedPage Today: medpagetoday.com/special-rep…
Numinus retweeted
#WorldSuicidePreventionDay is a reminder of how important it is to look out for one another. If you or someone close to you is struggling, @IASPinfo has many resources available to help. #WSPD2024 iasp.info/
Numinus retweeted
“Following our productive Type B meeting, we continue to expect to commence our Phase 3 pivotal program in late summer,” said @insidepharma, Chief Executive Officer of Cybin.
Read more: loom.ly/4r6Nng0
#Breathrough #Neuropsychiatiry #Biotechnology
Numinus retweeted
Research shows promising advancements in psychedelic medicine. @ReidRobison, Senior Principal Investigator at @NuminusHealth shares how MindMed’s investigational treatment in development may revolutionize mental health treatment. Link to @GoHealio video in comments.
Numinus retweeted
"For psychedelics to return to being psychedelically effective, we should use them to overturn the larger factory orientation in psychological care, not to join it."
theguardian.com/commentisfre…
Numinus retweeted
"Psychedelic Medicine Has a Therapy Problem" @TheAtlantic
It has been a disappointing, but not back-breaking, few days for the field. Let's address the issues head on.
theatlantic.com/health/archi…
Numinus retweeted
Learn more about #CYB004: Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD: cybin.com/cyb004/ ↩️
#MentalHealth #Biotechnology
Numinus retweeted
MDMA-assisted therapy is actually changing lives.
Bringing back my interview with @tferriss on topics we’ve both studied and supported including MDMA-assisted therapy, what it can do to heal trauma, and the exciting future where curing mental illness could actually be possible.
podcasts.apple.com/us/podcas…
Numinus retweeted
According to @PsychToday, 30% of adults in North America experience anxiety, but only 1/3 of them are properly diagnosed. Both awareness and diagnosis are vital for better mental health care.
Which of the following can be symptoms of GAD?
(Check back next week for the answer!)
9%Trouble falling asleep
7%Difficulty focusing
2%Upset stomach or nausea
81%All of the above
97 votes • Final results Numinus retweeted
FDA advisors voted against MDMA therapy – researchers are still fighting for it bbc.com/future/article/20240…
Numinus retweeted
Check out today’s news release regarding our development program for MM120 in the treatment of generalized anxiety disorder in adults.
ir.mindmed.co/news-events/pr…
Numinus retweeted
GAD (Generalized Anxiety Disorder) involves constant, excessive worry about everyday issues, often without a clear cause, over an extended period of time.
We aspire to improve the treatment of GAD through research, science, and the novel use of psychedelics.
Numinus retweeted
Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain benzinga.com/markets/cannabi… via @Benzinga
Numinus retweeted
Amanda Feilding discusses the beginnings of research into #microdosing for Alzheimer's.
Clip from the short film, The Queen of Psychedelics, by Alice Rausch, available in full on the Beckey Foundation Youtube channel.
Numinus retweeted
New: FDA tags on an extra hour to its Advisory Committee schedule to allow for 1:45-minutes worth of oral comments during the public hearing section.
Originally, just one hour had been set aside for this section of the meeting.
BREAKING: The FDA announced today that it is extending the advisory committee meeting on MDMA-assisted therapy to accommodate additional oral presentations from the public. The open public hearing is now scheduled for 2-3:45pm ET. Speakers only have 3 mins fda.gov/advisory-committees/…